Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Rectal Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Colonic Neoplasms 3Liver Neoplasms 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Stomach Neoplasms 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

Fluorouracil 98Oxaliplatin 94Leucovorin 86Irinotecan 70Gemcitabine 66Bevacizumab 62Capecitabine 60Cetuximab 42pembrolizumab 37Cisplatin 30Nivolumab 25Drug Therapy 25130-nm albumin-bound paclitaxel 22Specimen Handling 20Folfox protocol 20Panitumumab 19Paclitaxel 19Magnetic Resonance Spectroscopy 18Albumin-Bound Paclitaxel 17Biopsy 16IFL protocol 15Floxuridine 15Docetaxel 15Cyclophosphamide 15Sorafenib 14regorafenib 12Erlotinib Hydrochloride 12aflibercept 11Radiofrequency Ablation 11fludarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Pharmacogenomic Testing × Gastrointestinal × Clear all
NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Federation Francophone de Cancerologie Digestive

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡